Hua Medicine Reports Progress on Diabetes Drug

Hua Medicine of Shanghai announced it will start a Phase Ib trial of its glucokinase activator (GKA) treatment for type 2 diabetes. In the Phase Ia trial, HMS5552 produced positive results in healthy volunteers. The Phase Ib trial will test the drug in type 2 diabetics. Hua, which in-licensed the second generation GKA drug from Roche, holds global rights to HMS5552. More details.... Stock Symbol: (SIX: ROG) Share this with colleagues: // //